AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 42 min read$RARE

RARE Maintained by Goldman Sachs -- Price Target Lowered to $19.

Goldman Sachs maintained a Neutral rating for Ultragenyx Pharmaceutical (RARE) but lowered its price target to $19.00 from $28.00, citing concerns about growth and profitability. The stock is currently trading at $15.76, with a GF Value™ of $45.26, suggesting it is undervalued by 65.2%. Ultragenyx has a GF Score™ of 68/100, indicating moderate overall performance with strengths in growth but weaknesses in profitability and financial strength.

Original reporting
gurufocus.com
Published Sep 4, 2026, 6:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RARE
Bearish
medium confidence
Mentioned
$RARE
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RAREBearishMed
01

Why it matters

The downgrade could trigger further sell‑offs, but the stock remains significantly undervalued per GuruFocus metrics.

02

Market read

Analyst target cut is a fresh catalyst for RARE, likely influencing short‑term trading decisions.

03

What to watch

Potential pipeline milestones and upcoming regulatory decisions could offset short‑term concerns.

Relevance 6/10Novelty 6/10Timing: today

Background

Goldman Sachs' price‑target reduction follows a broader trend of analyst downgrades for Ultragenyx.

Company-level read

Ticker impact

$RAREBearishMedium confidence
Context

Goldman Sachs maintained a Neutral rating on Ultragenyx (RARE) and cut its price target to $19 from $28.

Expected impact

Potential short-term price decline toward $18‑$20 range.

Evidence & confidence

Target cut of 32% reflects concerns on growth and profitability, likely prompting sell‑offs.

Market effects

Sector

May weigh on other rare‑disease biotech stocks.

Regional

Limited to US biotech sector.

Global

Minimal global effect.

Counterpoint

What could challenge this read

Some investors may see the valuation gap as a buying opportunity if the company can improve cash flow.

Key entities

  • company
    Ultragenyx Pharmaceutical

    Biopharma focused on rare diseases, ticker RARE.

  • analyst
    Goldman Sachs

    Maintained Neutral rating, lowered price target.

Read at source← All news

Related articles

SEP 17
$RAREHighAI 9/10

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the

SEC EDGAR 8-K1 min
SEP 17
$RAREHighAI 9/10

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx Pharmaceutical (RARE) shares rose 10% after the FDA approved Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This is the first FDA-authorized treatment for this rare pediatric disease. The therapy showed improved cognitive function in clinical trials but carries risks like liver enzyme increases and potential long-term tumor development.

investing.com2 min
SEP 17
$RAREHighAI 9/10

US FDA approves Ultragenyx's gene therapy for rare disorder

The US FDA has approved a gene therapy developed by Ultragenyx Pharmaceutical Inc. for the treatment of a rare disorder. The therapy, designed for patients with a specific genetic condition, marks a significant milestone in the company's pipeline. According to the FDA, this approval provides a new treatment option for a previously underserved patient population.

tradingview.com1 min
SEP 4
$RAREHighAI 9/10

Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint

Ultragenyx (RARE) shares dropped 44.7% premarket after its Phase 3 Aspire study for apazunersen in Angelman syndrome missed primary and key secondary endpoints. Analysts downgraded the stock, with price targets lowered significantly. Shares fell below their 52-week low. According to the company, no meaningful differences were found between treatment and placebo groups.

yahoo.com2 min
SEP 4
$RAREHighAI 8/10

RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial

Ultragenyx Pharmaceutical Inc. (RARE) stock rose 3.57% after positive coverage of its rare disease pipeline. However, it later plunged 45% due to the failure of the GTX-102 Phase 3 trial. The company reported $214M in revenue and an 87.8% gross margin but posted a net loss of $92M. Analysts have mixed views, with some cutting price targets while others maintain an Overweight rating. The stock is highly volatile, trading at $15.35 after the drop.

stockstotrade.com2 min